Table 1.
Treatment with anti-CD40 Ab does not alter the frequency of MHV-68-specific CD8 T cells in BAL or spleen of MHC Class II −/− mice
| Mice | Treatment | Percentage IFN-γ-positive of
total CD8+ population
|
Total cell
no./mouse
|
n | ||||
|---|---|---|---|---|---|---|---|---|
| BAL
|
Spleen
|
|||||||
| p56 | p79 | p56 | p79 | BAL (×105) | Spleen (×107) | |||
| −/− | Control | 5.0 ± 2.0 | 6.1 ± 3.1 | 1.4 ± 0.6 | 1.0 ± 0.2 | 4.8 ± 1.8 | 6.1 ± 2.0 | 7 |
| −/− | Anti-CD40 | 4.4 ± 1.8 | 5.8 ± 4.3 | 1.5 ± 0.9 | 1.2 ± 0.3 | 4.1 ± 2.0 | 7.4 ± 2.3 | 7 |
| +/+ | None | 2.5 | 1.5 | 0.5 | 1.4 | 2.7 | 7.3 | 2 |
MHC Class II −/− or +/+ mice were infected with 2 × 104 pfu MHV-68, and BAL and spleen cells were harvested 60 days after infection. MHC Class II −/− mice were treated with 100 μg anti-CD40 or control antibody i.v. 1 and 15 days after infection. BAL or spleen cells were stimulated for 6 h with either p56 or p79 peptides in the presence of monensin prior to staining for CD8 and IFN-γ. Results are shown as mean ± SD. n, total number of mice analyzed.